Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 6/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | SORD | Q00796 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4327178 | 0.82 | KDM4E (0.49) | MAPTKDM4E | |
| Hydrochloric Acid SCHEMBL4483202 | 0.80 | KDM4E (0.48) | MAPTKDM4E | |
| SCHEMBL5458689 | 0.79 | ACHE (0.56) | OGAACHEMAPT | |
| SCHEMBL5458684 | 0.78 | OGA (0.44) | OGAACHEKDM1AKDM4E | |
| SCHEMBL29958994 | 0.77 | HRH4 (0.56) | OGAACHE | |
| SCHEMBL4948656 | 0.77 | HRH4 (0.56) | OGAACHE | |
| SCHEMBL15740608 | 0.77 | OGA (0.42) | OGAACHEKDM1ASORDKDM4E | |
| SCHEMBL4723792 | 0.77 | OGA (0.56) | OGAACHEKDM1ASORD | |
| SCHEMBL4484074 | 0.75 | GRIN2D (0.48) | KDM4E | |
| SCHEMBL4505689 | 0.75 | ACHE (0.43) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1917262-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-12-14 | — | — | EP | disclosed |
| US-7491821-B2 | 2-(4-fluorophenyl)-4-propyl-oxazole-5-carboxylic acid {2-[4-(6-aminopyridin-2-yl)-piperazin-1-yl]-1-methyl-ethyl}amide; purinergic receptor antagonists, analgesics; urogenital, gastointestinal and respiratory system disorders | ROCHE PALO ALTO LLC (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1917262-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007020194-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037974-A1 | Inhibitors of P2X3 | ROCHE PALO ALTO LLC | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037974-A1 | Inhibitors of P2X3 | P2RX3, P2RX4, P2RX5 | OGA 1681/4885ACHE 1245/4885KDM1A 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.